Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters

NCT00006083 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT00006083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2000
Completion date
November 30, 2000
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, chronic myeloproliferative disorders, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, precancerous/nonmalignant condition, unspecified adult solid tumor, protocol specific, veno-occlusive disease